Last reviewed 2026-05-27 · How we verify

Tetrucid (SULFIRAM)

Phase 2 active Small molecule ✓ Verified May 2026

Tetrucid (generic name: SULFIRAM) is a drug. It is currently in Phase 2 development for Alcoholism.

Tetrucid works by inhibiting the enzyme aldehyde dehydrogenase, which breaks down alcohol into a less toxic compound.

Tetrucid is a small molecule with the synonyms Sulfiram, Sulfiram, Sulfirame, and Tetmosol.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SULFIRAM
Modality	Small molecule
Therapeutic area	Gastroenterology
Phase	Phase 2

Mechanism of action

When you drink alcohol, your body breaks it down into a toxic compound called acetaldehyde. Tetrucid blocks the enzyme that's supposed to break down acetaldehyde, making you feel sick when you drink. This makes it less appealing to drink, which can help people stop or cut back on drinking.

Approved indications

Alcoholism

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tetrucid CI brief — competitive landscape report
Tetrucid updates RSS · CI watch RSS

Frequently asked questions about Tetrucid

What is Tetrucid?

Tetrucid (SULFIRAM) is a Small molecule drug, indicated for Alcoholism.

How does Tetrucid work?

Tetrucid works by inhibiting the enzyme aldehyde dehydrogenase, which breaks down alcohol into a less toxic compound.

What is Tetrucid used for?

Tetrucid is indicated for Alcoholism.

What is the generic name of Tetrucid?

SULFIRAM is the generic (nonproprietary) name of Tetrucid.

What development phase is Tetrucid in?

Tetrucid is in Phase 2.

Therapeutic area: All drugs in Gastroenterology
Indication: Drugs for Alcoholism

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing